Drugs / B2278
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07265349 | Dec 2025 → Dec 2026 expected | heart failure | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B2278 | “B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord.” NCT07265349 ↗ |
| Modality | Cell therapy | “B2278 is mesenchymal stem cells derived from human umbilical cord.” NCT07265349 ↗ |
| Route | Other | “intramyocardial injection into the epicardium” NCT07265349 ↗ |